These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25469833)

  • 41. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
    Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
    Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
    Li X; Jia X; Niu H
    Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
    Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
    Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
    Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
    Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G; Waxman DJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
    Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
    Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doxorubicin-loaded NaYF4:Yb/Tm-TiO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers.
    Zeng L; Pan Y; Tian Y; Wang X; Ren W; Wang S; Lu G; Wu A
    Biomaterials; 2015 Jul; 57():93-106. PubMed ID: 25913254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells.
    Liu R; Zhang Y; Chen Y; Qi J; Ren S; Xushi MY; Yang C; Zhu H; Xiong D
    J Pharm Sci; 2010 Jul; 99(7):3266-75. PubMed ID: 20112430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y; Wang Y; Zhang Y; Wei D
    Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
    Xu HB; Li L; Fu J; Mao XP; Xu LZ
    Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts.
    Li C; Xue HG; Feng LJ; Wang ML; Wang P; Gai XD
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4437-4445. PubMed ID: 29077148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
    Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
    Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance.
    Liu J; Ye Z; Xiang M; Chang B; Cui J; Ji T; Zhao L; Li Q; Deng Y; Xu L; Wang G; Wang L; Wang Z
    Biomaterials; 2019 Dec; 223():119475. PubMed ID: 31520888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
    Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
    Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.